Drugs.com
DECEMBER 26, 2024
THURSDAY, Dec. 26, 2024 -- Migraine patients often suffer a long time before docs zero in on the best dosage for drugs designed to prevent their terrible symptoms. But a recently approved daily migraine pill called Qulipta (atogepant) appears to be.
Science Daily: Pharmacology News
DECEMBER 25, 2024
Scientists have developed an innovative therapeutic platform by mimicking the intricate structures of viruses using artificial intelligence (AI).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Chemical Biology and Drug Design
DECEMBER 23, 2024
We have discovered a gefitinib derivative that can inhibit IDO1 enzyme activity in Hela cells, thereby inducing apoptosis in these cells. ABSTRACT Cervical cancer is the fourth most common cancer among women globally. Its development is closely linked to accelerated cell cycle progression and the inhibition of apoptosis in cervical cancer tissues. Gefitinib has demonstrated efficacy in inhibiting cervical cancer cells, and the 1,2,3-triazole structure is widely recognized for its role in inducin
Drug Target Review
DECEMBER 23, 2024
Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. While these therapies hold great promise for improving cancer treatment outcomes, their development presents significant challenges, especially in achieving the optimal balance between efficacy and safety.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drugs.com
DECEMBER 23, 2024
December 23, 2024 -- Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Perficient: Drug Development
DECEMBER 27, 2024
Our new Agentforce Resource Center is here! This comprehensive resource is crafted to help businesses unlock tailored AI solutions, explore industry-specific use cases, and assess their Salesforce readiness. In the ever-evolving digital landscape, businesses need cutting-edge solutions to stay competitive and drive unparalleled results. Salesforce Agentforce 2.0 is here to revolutionize your operations with its suite of assistive and autonomous AI agents.
Fierce BioTech
DECEMBER 23, 2024
Pharmacy Considerations for Early Phase Trials dwunderlin Mon, 12/23/2024 - 15:20 Wed, 02/12/2025 - 14:00 Resource Type Webinar Todd Janssen, RPh Donnie Keeney, PharmD Sheri Sander Duration 60 Minutes From sterile compounding to handling controlled substances, a crucial aspect of conducting successful early phase trials is the careful preparation of both investigational and non-investigational products to be used in a clinical trial setting.
Drugs.com
DECEMBER 23, 2024
MONDAY, Dec. 23, 2024 -- The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound. In a news release published Dec. 20, the FDA.
Science Daily: Pharmacology News
DECEMBER 23, 2024
Even highly realistic androids can cause unease when their facial expressions lack emotional consistency. Traditionally, a 'patchwork method' has been used for facial movements, but it comes with practical limitations. A team developed a new technology using 'waveform movements' to create real-time, complex expressions without unnatural transitions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 23, 2024
VICTRELIS (boceprevir) Merck sharp dohme Patent: RE43298 Expiration: Dec 22, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Alta Sciences
DECEMBER 23, 2024
Webinar-Nanomilling-Updated 2024 tchichekian Mon, 12/23/2024 - 20:39 Image Webinar_CDMO Nanosuspension Formulations.
Drugs.com
DECEMBER 21, 2024
SATURDAY, Dec. 21, 2024 -- The holiday spirit is infectious, even for people suffering from dementia.But family and friends might need to make some slight adjustments to help a dementia patient better enjoy the holidays, the Alzheimers Foundation o.
Science Daily: Pharmacology News
DECEMBER 27, 2024
The creation of more fox-free safe havens and greater collaboration between government and landowners is needed to ensure the survival of a species of wallaby, an expert argues. The Parma wallaby, also known as the white-throated wallaby, is listed as a vulnerable species in Australia, while the International Union for Conservation of Nature (IUCN) classifies it as Near Threatened.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Covalent Modifiers
DECEMBER 27, 2024
Guiqun Wang, Nico J. Seidler, Sandra Rhm, Yufeng Pan, Xiaojun Julia Liang, Lisa Haarer, Benedict-Tilman Berger, Saran Aswathaman Sivashanmugam, Valentin R. Wydra, Michael Forster, Stefan A. Laufer, Apirat Chaikuad, Matthias Gehringer, Stefan Knapp Angew. Chem. Int. Ed. 2024 , e202419736 [link] Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases.
Alta Sciences
DECEMBER 23, 2024
HPAPI Manufacturing Webinar_Updated 2024 tchichekian Mon, 12/23/2024 - 20:18 Image slide1.
Drugs.com
DECEMBER 27, 2024
FRIDAY, Dec. 27, 2024 -- The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian.
Chemical Biology and Drug Design
DECEMBER 26, 2024
New ()- cis - N -normetazocine derivatives were developed (compounds 3 8 ) and the most interesting compound 7 showed a significant MOR affinity and a similar docking mode with respect to previously synthesized compounds. Moreover, the limited BBB permeability of compound 7 suggests its potential for development as a peripherally restricted opioid ligand.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Covalent Modifiers
DECEMBER 25, 2024
Juan Pablo Cerutti, Lucas Abreu Diniz, Viviane Corra Santos, Salom Catalina Vilchez Larrea, Guillermo Daniel Alonso, Rafaela Salgado Ferreira, Mario Alfredo Quevedo, and Wim Dehaen ACS Medicinal Chemistry Letters 2024 DOI: 10.1021/acsmedchemlett.4c00460 Cruzipain (CZP) is an essential cysteine protease of Trypanosoma cruzi, the etiological agent of Chagas disease, and a promising druggable target.
Alta Sciences
DECEMBER 23, 2024
HPAPI Manufacturing Webinar_Updated 2024 tchichekian Mon, 12/23/2024 - 20:18 Image High Potency Manufacturing Solutions.
Drugs.com
DECEMBER 26, 2024
THURSDAY, Dec. 26, 2024 -- Female stroke victims are less likely than men to take drugs that could lower their odds of a second stroke.Women are 80% more likely to report that they dont take cholesterol-lowering medications as prescribed, a new s.
Drug Patent Watch
DECEMBER 26, 2024
The biopharmaceutical sector has made significant strides in developing and delivering effective drugs to improve health and combat diseases. However, the high cost of prescription drugs remains a significant barrier to access for many patients. One key solution to this issue lies in the role of generic drugs, which are significantly cheaper than branded products and can help reduce the financial burden on patients and the healthcare system.
Covalent Modifiers
DECEMBER 21, 2024
Nir London Chemical Reviews Article ASAP DOI: 10.1021/acs.chemrev.4c00570 Molecules that are able to induce proximity between two proteins are finding ever increasing applications in chemical biology and drug discovery. The ability to introduce an electrophile and make such proximity inducers covalent can offer improved properties such as selectivity, potency, duration of action, and reduced molecular size.
Alta Sciences
DECEMBER 23, 2024
HPAPI Manufacturing Webinar_Updated 2024 tchichekian Mon, 12/23/2024 - 20:18 Image High Potency Manufacturing Solutions_1.
Drugs.com
DECEMBER 27, 2024
FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohns disease.A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (.
FDA Law Blog: Drug Discovery
DECEMBER 23, 2024
By Mark A. Tobolowsky & Frank J. Sasinowski The Winter Solstice, signifying the shortest day of the year, was Saturday, December 21. Although the earliest sunset of the year was actually in early December, this day also marked another premature sunset the beginning of the end of the rare pediatric disease priority review voucher program. As we blogged recently, the program has had scheduled sunset dates from its very beginning, which have been repeatedly extended.
Covalent Modifiers
DECEMBER 22, 2024
F angyuan Chen, Qingmei Liu, Lei Ma, Cuishi Yan, Haiman Zhang, Zhi Zhou, and Wei Yi Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c02803 Recent studies have identified selective peroxisome proliferator-activated receptor (PPAR) modulators, which synergistically engage in the inhibition mechanism of PPAR-Ser273 phosphorylation, as a promising approach for developing safer and more effective antidiabetic drugs.
Alta Sciences
DECEMBER 23, 2024
HPAPI Manufacturing Webinar_Updated 2024 tchichekian Mon, 12/23/2024 - 20:18 Image High Potency Manufacturing Solutions_2.
Expert insights. Personalized for you.
299 
Let's personalize your content